As Bachem is the world’s leading company in developing and manufacturing peptides and oligonucleotides, we receive a lot of interest about our company news and activities.
Learn more about what is happening at Bachem, what activities we have coming up, and what events you can meet us both virtually and in-person.
All Bachem news
- All
- Ad-hoc
- CMC development
- Commercial APIs
- Finance
- Innovation
- Knowledge
- News
- Oligonucleotides
- Peptides
- Press
- Research & specialties
- Services & capabilities
- Sustainability
- Team
- Trends
01Dec2023
Jérôme Kaeslin receives ETH medal for his outstanding dissertation
Jérôme Kaeslin receives ETH medal for his outstanding dissertation...
29Nov2023
Scalable tag-assisted one-pot liquid-phase oligo synthesis
Using tag-assisted one-pot liquid-phase oligonucleotide synthesis for high amount of oligos with low...
15Nov2023
Elena Zakharova Wins Cancer Drug Discovery Research Award
Elena Zakharova Wins Cancer Drug Discovery Research Award...
27Oct2023
Back to stirred vessels and on to metric tons of oligonucleotides
Stirred-bed technology represents an economical solution to manufacture oligonucleotides on a large...
24Oct2023
The Latest Trends in Peptides and Oligonucleotides
The rising interest in TIDES molecules has numerous aspects. They all favor peptides, oligonucleotid...
23Oct2023
Octreotide acetate – a complex molecule for a complex disease
Throughout our lives, intricate mechanisms regulate our body's growth. A glitch in the growth hormon...
15Sep2023
Bachem reorganizes responsibilities in the Corporate Executive Committee and increases focus on capacity expansion and efficiency improvement
Bachem reorganizes responsibilities in the CEC and concentrates even more on expanding capacity and ...
14Sep2023
Glucagon-like peptide 1 (GLP-1)
An explanation of what a glucagon-like peptide 1 (GLP-1) is, how the receptor agonists work and what...
11Aug2023
How can pharma and biotech benefit from strategic alliances?
Explaining the benefits from strategic alliances between two companies that have decided to share re...
27Jul2023
Bachem increases sales slightly in the first half of 2023
Bachem increases sales slightly in the first half of 2023....
24Jul2023
How to increase sustainability for large-scale peptide API purification?
The peptide drug market has experienced significant growth in recent years and is expected to contin...
19Jul2023
Great to be part of a company that stays true to its roots!
Learn why Rico enjoys being part of Bachem, a fast-growing company that stays true to its roots....
14Jul2023
IEA Environmental Excellence Award 2023
We were awarded the IEA Environmental Excellence Award, highlighting our commitment to environmental...
03Jul2023
Meet Iain Pritchard – New Site Manager at Bachem St. Helens
We are pleased to announce that Iain Pritchard will take on the role of Site Manager in St. Helens (...
05Jun2023
Solid Phase Peptide Synthesis (SPPS) explained
Learn about the Solid Phase Peptide Synthesis (SPPS). A technique used for producing peptides effici...
12May2023
Purification – a bottleneck for large-scale manufacturing of oligonucleotide API?
In oligonucleotide manufacturing, purification is a critical step to ensure the final product is pur...
25Apr2023
Manufacturing complex Peptide APIs
An Interview about the manufacturing of complex peptide APIs...
20Apr2023
Bachem Annual General Meeting 2023
Bachem Holding AG (“Bachem”, SIX: BANB) announced today that its Annual General Meeting (AGM) 20...
Next events coming up
Swiss RNA Therapeutics Summit 2024
Swiss RNA Therapeutics Summit 2024
Bachem is attending the Swiss RNA Therapeutics Summit 2024
Full event calendar
Interested in joining at one of our upcoming exhibitions, conferences or webinars? View our full calendar of events.